Loading...
XNAS
ABUS
Market cap1.02bUSD
Jul 09, Last price  
5.14USD
1D
-1.53%
1Q
23.86%
Jan 2017
109.80%
IPO
-51.05%
Name

Arbutus Biopharma Corp

Chart & Performance

D1W1MN
XNAS:ABUS chart
P/E
—
P/S
72.10
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.37%
Rev. gr., 5y
15.29%
Revenues
14m
+128.21%
13,604,33115,923,3499,639,75013,779,40521,351,32216,304,54714,180,79215,464,15015,000,00024,873,0001,500,00010,700,0005,900,0006,011,0006,914,00010,988,00039,019,00018,141,0006,171,00014,083,000
Net income
-34m
L-52.09%
18,080,5270000029,947,878-14,064,226-38,800,000-61,121,000-384,100,000-84,400,000-57,100,000-153,723,000-63,745,000-76,247,000-69,456,000-72,849,000-69,920,000-33,501,000
CFO
-40m
L-38.88%
00000033,270,564-6,738,559-12,421,000-54,785,000-57,885,000-48,600,000-67,900,000-71,006,000-51,441,000-67,532,000-35,356,000-85,936,000-64,850,000-39,637,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
URL
https://www.arbutusbio.com/
IPO date
Nov 13, 2010
Employees
96
Domiciled in
US
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT